NO20054744L - Behandling av Alzheimers sykdom - Google Patents

Behandling av Alzheimers sykdom

Info

Publication number
NO20054744L
NO20054744L NO20054744A NO20054744A NO20054744L NO 20054744 L NO20054744 L NO 20054744L NO 20054744 A NO20054744 A NO 20054744A NO 20054744 A NO20054744 A NO 20054744A NO 20054744 L NO20054744 L NO 20054744L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
treatment
ifn
treat
Prior art date
Application number
NO20054744A
Other languages
English (en)
Inventor
Luigi Grimaldi
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20054744L publication Critical patent/NO20054744L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår anvendelse av interferon-ß (IFN-ß) til å behandle og/eller forhindre Alzheimers sykdom (AD), Creutzfeld-Jakob sykdom (CJD) eller Gerstmann- Sträussler-Scheinker sykdom (GSSD). Den angår ytterligere anvendelse av IFN-ß i kombinasjon med et middel til behandling av Alzheimers sykdom for å behandle og/eller forhindre Alzheimers sykdom. Anvendelse av IFN-ß i kombinasjon med en cholinesteraseinhibitor for å behandle og/eller forhindre tidlig inntredende Alzheimers sykdom er foretrukket.
NO20054744A 2003-03-19 2005-10-14 Behandling av Alzheimers sykdom NO20054744L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100716 2003-03-19
PCT/EP2004/050316 WO2004082706A2 (en) 2003-03-19 2004-03-17 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders

Publications (1)

Publication Number Publication Date
NO20054744L true NO20054744L (no) 2005-10-14

Family

ID=33016977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054744A NO20054744L (no) 2003-03-19 2005-10-14 Behandling av Alzheimers sykdom

Country Status (14)

Country Link
US (1) US20070110715A1 (no)
EP (1) EP1620124A2 (no)
JP (1) JP2006520368A (no)
KR (1) KR20050115279A (no)
CN (1) CN1791423A (no)
AR (1) AR043660A1 (no)
AU (1) AU2004222529A1 (no)
BR (1) BRPI0408491A (no)
CA (1) CA2516990A1 (no)
EA (1) EA009668B1 (no)
IL (1) IL170751A0 (no)
MX (1) MXPA05009986A (no)
NO (1) NO20054744L (no)
WO (1) WO2004082706A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006136361A (ru) * 2004-04-14 2008-04-20 Уорнер-Ламберт Компани Ллс (Us) Терапевтическая комбинация для лечения болезни альцгеймера
US7695911B2 (en) * 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
EP2001463B1 (en) * 2006-03-20 2013-07-03 Council of Scientific and Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
CN101116670B (zh) * 2006-08-01 2010-11-10 广州和竺生物科技有限公司 可提供活性甲基或参与甲基转移的化合物作为制备治疗病毒性疾病的药的应用
MX2009001937A (es) * 2006-08-21 2009-04-30 Novartis Ag Biomarcadores para el progreso de la enfermedad de alzheimer.
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
EP2364150A1 (en) * 2008-11-11 2011-09-14 Targacept Inc. Treatment with alpha 7-selective ligands
US20110081428A1 (en) * 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CN102382096A (zh) * 2011-09-06 2012-03-21 清华大学 异香豆素及其衍生物的制备方法
CN102707065A (zh) * 2012-03-23 2012-10-03 常熟市虞山绿茶有限公司 Prohibitin蛋白抗体在制备诊断老年性痴呆的试剂盒中的应用
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US9116974B2 (en) * 2013-03-15 2015-08-25 Robert Bosch Gmbh System and method for clustering data in input and output spaces
CN106754995B (zh) * 2016-11-25 2020-07-10 山东农业大学 中华蜜蜂AccCDK5基因及AccCDK5r1基因及其应用
RU2729391C2 (ru) * 2018-12-28 2020-08-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело, способное нейтрализовать биологическую активность интерферона бета-1а человека
CN109518211B (zh) * 2019-01-08 2020-11-06 合肥工业大学 一种芳香偶酰类化合物的电化学合成方法
US20220378741A1 (en) * 2019-11-04 2022-12-01 Ck Regeon Inc. Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof
WO2023080687A1 (ko) * 2021-11-03 2023-05-11 가천대학교 산학협력단 아밀로이드 베타 멀티머 저해 약물의 고속 대량 스크리닝 방법 및 독소루비신 또는 이의 유도체를 포함하는 아밀로이드 베타의 올리고머화 또는 섬유화 억제용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057879A1 (en) * 1999-03-26 2000-10-05 Barry Reisberg Treatment of brain changes with myelin protective agents
ATE300952T1 (de) * 1999-12-09 2005-08-15 Chiron Corp Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem

Also Published As

Publication number Publication date
WO2004082706A2 (en) 2004-09-30
WO2004082706A3 (en) 2005-01-13
EA200501479A1 (ru) 2006-02-24
US20070110715A1 (en) 2007-05-17
EA009668B1 (ru) 2008-02-28
MXPA05009986A (es) 2005-11-04
IL170751A0 (en) 2011-08-01
KR20050115279A (ko) 2005-12-07
CN1791423A (zh) 2006-06-21
BRPI0408491A (pt) 2006-04-04
AU2004222529A1 (en) 2004-09-30
CA2516990A1 (en) 2004-09-30
EP1620124A2 (en) 2006-02-01
AR043660A1 (es) 2005-08-03
JP2006520368A (ja) 2006-09-07

Similar Documents

Publication Publication Date Title
NO20054744L (no) Behandling av Alzheimers sykdom
GB0223040D0 (en) Therapeutic compounds
ATE368031T1 (de) Neue gamma secretase inhibitoren
GB0225474D0 (en) Therapeutic agents
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
GB0223038D0 (en) Therapeutic compounds
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60112957D1 (de) Sulfamide als gamma-secretase-inhibitoren
DE60330485D1 (de) Zur behandlung von diabetes
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE60226723D1 (de) Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
MY139368A (en) Novel cyclohexyl sulphones
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
DK0707477T3 (da) Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application